Covid-19 roundup: Pfizer, BioNTech's Omicron-specific shot delayed as surge wanes, while Moderna eyes August rollout
A slower-than-expected data gathering process is delaying Pfizer and BioNTech’s efforts to deliver an Omicron-specific Covid-19 vaccine, BioNTech CEO Uğur Şahin told Germany’s Bild, per Reuters.
The two partners previously expected to launch the shot by the end of March. They kicked off a study in late January to test an mRNA jab that’s tailored to the Omicron variant of SARS-CoV-2, both as a booster to two doses of the original vaccine and as a full three-dose series.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
